Von Eschenbach Joins Histosonics Board
Ann Arbor, MI--Former FDA Commissioner Andrew von Eschenbach, M.D., has joined the board of Histosonics, which is developing its Histotripsy technology for non-invasive surgery. Dr. von Eschenbach is recognized around the world as a leader in urology and cancer treatment, as well as in healthcare policy and regulation.
Histosonics' first market application for its Histotripsy technology is benign prostate hyperplasia (BPH) or enlarged prostate gland, which affects over two million older men in the U.S. alone. The Histotripsy platform has been tested successfully in pre-clinical experiments that demonstrate its feasibility for tumor excision throughout the body.
"Dr. von Eschenbach brings a broad vision and wealth of experience from both the private and public sectors to the Histosonics Board of Directors," said Tom Davison, Ph.D., Chairman and CEO of the company. "His commitment to safe and effective healthcare and especially cancer therapy aligns precisely with Histosonic's vision and long term strategy. All of us on the Histosonics and our partners at the University of Michigan are honored to welcome Dr. von Eschenbach to our board."
Dr. von Eschenbach commented, "I am delighted and honored to be an integral part of an exciting opportunity to care for patients." Dr. von Eschenbach has led a distinguished career, includilng as Chairman of the Department of Urologic Oncology at the University of Texas M.D. Anderson Cancer Center. In September 2005 he was appointed interim commissioner of the FDA, a position to which he was confirmed in December 2006. Prior to that apponitment, he was Director of the National Cancer Institute.
Find Out More About ESP
Andrew McColm (left front) and Mike Bunker (right rear) manage the Histosonics investment for Early Stage Partners.